Abstract
Neurofibromatosis type 1 (NF1) is a multisystem autosomal dominant genetic syndrome affecting 1 in 4000 individuals and characterized by heterozygous loss of the tumor suppressor gene, neurofibromin.1 Patients with NF1 develop benign skin, eye, and nervous system tumors and susceptibility to nervous system and other solid organ cancers.1,2 Biallelic loss of NF1 (OMIM 613113) leads to hyperactivation of RAS signaling pathways.3 Although patients with NF1 often present to dermatologists for skin concerns, the risk of basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and melanoma in these patients remains unclear.